Review Article

Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy

Kang Luo,1,2,3,4 Sun Woo Lim,1,2 Yi Quan,1,2 Sheng Cui,1,2 Yoo Jin Shin,1,2 Eun Jeong Ko,1,2,3 Byung Ha Chung,1,2,3 and Chul Woo Yang1,2,3

1Transplant Research Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4Department of Nephrology, Yanbian University Hospital, Yanbian, China

Correspondence should be addressed to Chul Woo Yang; yangch@catholic.ac.kr

Received 19 March 2019; Revised 2 September 2019; Accepted 7 September 2019; Published 17 October 2019

Academic Editor: Gabriele Saretzki

Copyright © 2019 Kang Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Calcineurin inhibitors (CNIs) are the most popular immunosuppressants in organ transplantation, but nephrotoxicity is a major concern. The common mechanism underlying chronic CNI nephropathy is oxidative stress, and the process of chronic CNI nephropathy is similar to that of aging. Current studies provide evidence that antiaging Klotho protein plays an important role in protecting against oxidative stress, and its signaling is a target for preventing oxidative stress-induced aging process. In this review, we focus on the association between Klotho and oxidative stress and the protective mechanism of action of Klotho against oxidative stress in chronic CNI nephropathy. In addition, we discuss the delivery strategy for Klotho in CNI-induced nephropathy.

1. Overview of Klotho in Human Disease

Klotho is an aging-suppressor gene [1, 2], and it encodes a single-pass transmembrane protein. The extracellular domain of Klotho protein is cleaved on the cell surface by membrane-anchored proteases and is released into the blood [3–5], urine [6–8], and cerebrospinal fluid [4]. Secreted Klotho proteins have diverse functions, including the regulation of multiple ion channels [6, 8–10] and oxidative stress [11–13].

Klotho is involved in various pathologies, such as atherosclerosis, heart failure, hypertension, acute kidney injury, chronic kidney disease, diabetes mellitus, and even cancer [14–17]. Interestingly, Klotho is highly expressed in the kidney [1], and its expression is suppressed under sustained stress conditions in several animal models [18–22] of kidney injury and in patients with chronic renal failure [23]. Thus, the role of Klotho in kidney injury has attracted increasing attention from researchers.

2. Overview of Chronic CNI Nephropathy

Calcineurin inhibitors (CNIs) are the most popular immunosuppressive drugs used for solid organ transplantation, and two CNIs [cyclosporine (CsA) and tacrolimus (TAC)] are available in clinical practice [24]. CNI exerts its immunosuppressive action by inhibiting calcineurin in T-cells. This inhibition then impairs translocation of the nuclear factor of activated T-cells [25–27], which regulates IL-2 transcription and thus T-cell activation [28–30]. Despite the specific inhibition of T-cell activation, long-term treatment with CNIs causes serious adverse effects, and nephrotoxicity is a major issue in solid organ transplantation.

Utilizing a well-established animal model, we and others have demonstrated that CNI causes low-grade ischemic injury by reducing renal blood flow and activating a complex network of proinflammatory and profibrotic mediators (for example, osteopontin [31, 32] and transforming growth factor β1 [33, 34]), along with the renin-angiotensin system
Using animal model of chronic CNI nephropathy, we first reported that CNI treatment decreased Klotho mRNA and protein in the mouse kidney in a dose- and time-dependent manner [43, 47] and Klotho expression was correlated with activity of renin-angiotensin system, tubulointerstitial fibrosis, and marker of oxidative stress (urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) excretion) [48]. This finding suggests that long-term treatment of CNI decreases Klotho expression in the kidney and Klotho is a useful marker to represent chronic CNI nephropathy.

A Klotho-deficient mouse aging model is useful to define the causal relationship between oxidative stress and Klotho. Kuro-o et al. reported that Klotho deficiency is closely related to cardiovascular diseases [1] and Klotho is an important humoral factor involved in oxidative stress regulation, endothelial dysfunction, cell proliferation, and apoptosis [49–51]. Using Klotho +/− mice, we found that Klotho deficiency renders the kidney more susceptible to TAC-induced injury, which was closely associated with aggravated TAC-induced oxidative stress [47]. These findings suggest strong associations between Klotho and CNI-induced oxidative stress and provide evidence that Klotho plays an important role in protecting against CNI-induced oxidative stress.

### 4. Protective Mechanism of Action of Klotho against CNI-Induced Oxidative Stress

Klotho is involved in several intracellular signaling pathways (PKC, FGF23, cAMP, TGF-β, p53/p21, Wnt signaling, and PD-L1/PD-1 p65 pathway) [52, 53], and many studies have reported the interactions among these pathways [54, 55]. In this review, we focus on the antioxidative function of Klotho via the intracellular phosphatidylinositol 3-kinase (PI3K)-Akt serine-threonine kinase (AKT) signaling pathway.

The PI3K-AKT signaling pathway regulates forkhead box protein O (FoxO) through phosphorylation. The AKT-mediated phosphorylation of FoxO inhibits FoxO activity by promoting its interaction with 14-3-3 proteins and nuclear exportation and also by inducing its proteasomal degradation [56]. FoxO3a can upregulate manganese superoxide dismutase (MnSOD) expression [2, 57, 58]. Thus, FoxO3a functions as a negative regulator of mitochondrial ROS production [59] and thereby closely associates with resistance to oxidative stress. In an experimental model of TAC-induced nephropathy, we found that concomitant Klotho treatment inhibits the PI3K/AKT-mediated phosphorylation of FoxO3a and enhances FoxO3a binding to the MnSOD promoter. Thus, Klotho increases MnSOD mRNA and protein expression in mitochondria and reduces TAC-induced mitochondrial dysfunction and ROS production [60]. Taken together, Klotho protects TAC-induced oxidative stress by negatively regulating the PI3K/AKT pathway and subsequently enhances FoxO3a-mediated MnSOD expression.

### 5. Role of Klotho in CNI-Induced Cell Death

Endoplasmic reticulum (ER) stress, a common cellular stress, is a potent trigger for autophagy, which is an important protective mechanism against various cellular stresses, including nutrient deprivation, hypoxia, and growth factor deprivation [61, 62]. Thus, the balance between ER stresses and autophagy is important to maintain cell viability, and excessive ER stress or impaired autophagy may cause apoptotic cell death. Recent reports showed that Klotho plays an important role in modulating ER signaling crosstalk between autophagy and apoptosis [49–51] and Klotho treatment alleviates ER stress in unilateral ureteral obstruction or attenuates oxidant-induced alveolar epithelial cell apoptosis [63]. In addition, the association between Klotho and autophagy has been reported in various diseases, such as Alzheimer’s disease,
acute kidney injury, chronic obstructive pulmonary disease, and lung cancer [64–67].

CNI-induced renal injury involves induction of the ER stress response and apoptosis [68, 69]. Kidneys treated with CNI for a short time adapt well to such stress by synthesizing molecular chaperones and activating autophagy process. However, prolonged ER stress by CNI exposure may cause apoptosis by depleting molecular chaperones and overloaded autophagosome [70, 71]. We recently reported that chronic CNI nephropathy is a state of excessive accumulation of autophagosome and impaired autophagy clearance [72] and Klotho treatment reduces the burden of autophagy vacuoles by improving autophagy clearance via activation of lysosomal function in CNI-induced nephrotoxicity [73]. We summarized the mechanism of protective effect of Klotho on CNI-induced autophagy cell death in Figure 2.

6. Delivering Strategy for Klotho

We and other researchers studied how to preserve Klotho against oxidative stress in kidney, and we reported that angiotensin II blockade, statin, and N-acetylcysteine are effective in preserving Klotho in experimental model of chronic CNI nephropathy [40, 42, 43]. However, it is not certain whether preservation of Klotho by these drugs is casually related to the antioxidant effect.

Accumulating evidence indicates that administration of exogenous Klotho is a rational strategy for the treatment of acute/chronic kidney diseases [74]. However, the half-life of recombinant Klotho is so short (7.2 h) that frequent injection (every day or every alternative day) is needed to achieve therapeutic efficacy [60, 75–77]. To overcome this limitation, we developed minicircle (MC) vector encoding Klotho protein. Using MC delivery, we can detect MC-Klotho until 30 days and MC-mediated Klotho protein until 10 days after single injection via the tail vein and at significantly higher levels than that of conventional vectors [78] (Figure 3). Thus, the MC-mediated vector encoding Klotho provides more long-term and stable Klotho expression than recombinant Klotho protein. We observed the effect of MC in an animal model of ischemia-reperfusion injury and obstructive nephropathy [78]. We expect that MC-mediated Klotho protein production may offer a new approach to Klotho delivery in clinical practice.
7. Conclusions
Klotho plays an important role in protecting against CNI-induced oxidative stress. Klotho and its signaling is an important target of preventing oxidative stress-induced organ injury.

Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions
Kang Luo and Sun Woo Lim equally contributed to this paper.

Acknowledgments
This study was supported by a grant of the Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI14C3417).
References


[16] S. J. Jeong, J. E. Song, S. B. Kim et al., “Plasma klotho levels were inversely associated with subclinical carotid atherosclerosi


Oxidative Medicine and Cellular Longevity

6


